We assessed the efficacy and safety of ramucirumab versus placebo in combination with second-line FOLFIRI ( leucovorin , fluorouracil , and irinotecan ) for metastatic colorectal cancer in patients with disease progression during or after first-line therapy with bevacizumab , oxaliplatin , and a fluoropyrimidine .